Tag Archives: Elemer Piros

Cantor Fitzgerald Keeps a Buy Rating on Rigel

In a report released today, Elemer Piros from Cantor Fitzgerald maintained a Buy rating on Rigel (NASDAQ: RIGL), with a price target of $6. The company’s shares opened today at $3.32. Piros observed: “Premature to Write-off IgAN for Now. Given

Zynerba Pharmaceuticals Gets a Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Zynerba Pharmaceuticals (NASDAQ: ZYNE) yesterday and set a price target of $20. The company’s shares closed yesterday at $10.53. According to TipRanks.com, Piros is ranked 0 out of 5 stars

Corbus Pharmaceuticals Gets a Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Corbus Pharmaceuticals (NASDAQ: CRBP) yesterday and set a price target of $32. The company’s shares closed yesterday at $6.85. According to TipRanks.com, Piros is ranked 0 out of 5 stars

Strongbridge Biopharma Plc Receives a Buy from Cantor Fitzgerald

In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Strongbridge Biopharma Plc (NASDAQ: SBBP), with a price target of $14. The company’s shares opened today at $7.65. Piros observed: “Added Focus on RECORLEV into

Cantor Fitzgerald Reiterates Their Buy Rating on Dynavax

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Dynavax (NASDAQ: DVAX) today and set a price target of $27. The company’s shares opened today at $17.35. Piros noted: “HEPLISAV-B Launched. Dynavax reported HEPLISAV-B, a two-dose hepatitis B vaccine,

Analysts’ Top Healthcare Picks: OCUL, CORI

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ocular Therapeutix (NASDAQ: OCUL) and Corium (NASDAQ: CORI) with bullish sentiments. Ocular Therapeutix (NASDAQ: OCUL) In a report released today, Elemer Piros